Pharmacology of cancer chemotherapy drugs for hyperthermic intraperitoneal peroperative chemotherapy in epithelial ovarian cancer

doi:10.5317/wjog.v2.i4.143

Advanced Search

BPG is committed to discovery and dissemination of knowledge

Home / Archive / Volume 2, Issue 4

This Article

Citation of this article

Corresponding Author of This Article

Research Domain of This Article

Article-Type of This Article

Open-Access Policy of This Article

Times Cited Counts in Google of This Article

Number of Hits and Downloads for This Article

Total Article Views (6169)

All Articles published online

The chart showing PDF series, HTML series, Figures (1-6) series, Tables (1-1) series.

Item

Count

PDF

486

HTML

3349

Figures (1-6)

158

Tables (1-1)

139

Sum=4132

Publishing Process of This Article

The chart showing Browse series, Download series.

Item

Count

Browse

1112

Download

925

Sum=2037

Nov 10, 2013 (publication date) through Jun 8, 2024

Times Cited of This Article

Times Cited (0)

Journal Information of This Article

Publication Name

World Journal of Obstetrics and Gynecology

ISSN

2218-6220

Publisher of This Article

Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA

Topic Highlight

World J Obstet Gynecol. Nov 10, 2013; 2(4): 143-152
Published online Nov 10, 2013. doi: 10.5317/wjog.v2.i4.143

Pharmacology of cancer chemotherapy drugs for hyperthermic intraperitoneal peroperative chemotherapy in epithelial ovarian cancer

Kurt Van der Speeten, Anthony O Stuart, Paul H Sugarbaker

Kurt Van der Speeten, Department of Surgical Oncology, Ziekenhuis Oost-Limburg, 3600 Genk, Belgium

Kurt Van der Speeten, University Hasselt, Life Sciences Faculty, Oncology Research Cluster, 3000 Hasselt, Belgium

Anthony O Stuart, Paul H Sugarbaker, Washington Cancer Institute, Washington Hospital Center, Washington, DC 20010, United States

Author contributions: All authors contributed the data analysis and discussion of this review.

Correspondence to: Kurt Van der Speeten, MD, PhD, Department of Surgical Oncology, Ziekenhuis Oost-Limburg, Schiepse Bos 6, 3600 Genk, Belgium. kurt.vanderspeeten@zol.be

Telephone: +32-89-326524 Fax: +32-89-326524

Received: December 13, 2012
Revised: June 16, 2013
Accepted: June 23, 2013
Published online: November 10, 2013

Core Tip

Core tip: Intraperitoneal (IP) chemotherapy is an important adjuvant treatment strategy in patients with advanced epithelial ovarian cancer. Although the clinical benefits have been demonstrated both in phase II and III trials, the pharmacologic rationale for this treatment strategy needs to be clarified. This manuscript reviews the pharmacokinetic and pharmacodynamic rationale of IP chemotherapy and analyzes the available data.